Business context and reporting period
This unaudited Form 10-Q is for the quarter ended September 30, 2022. Although the request metadata names Traws Pharma, the filing is for Onconova Therapeutics, Inc., a clinical-stage oncology biotech. Its programs include narazaciclib and rigosertib. Shares and per-share amounts reflect a 1-for-15 reverse split effective May 20, 2021.
Financial performance and position
- Revenue: $57,000 for the quarter and $170,000 for the nine months, unchanged from comparable 2021 periods; revenue was recognition of deferred upfront payments under the SymBio collaboration.
- Net loss: $5.4 million for the quarter versus $3.5 million in 2021; $13.5 million for nine months versus $12.4 million. Nine-month basic and diluted loss per share was $0.65, compared with $0.80.
- Operating expenses: Quarterly R&D rose 104% to $3.6 million, primarily from narazaciclib manufacturing costs; G&A declined 8% to $2.1 million. Nine-month R&D increased 38% to $7.6 million, while G&A fell 13% to $6.4 million.
- Cash flow: Operating cash use was $12.4 million for nine months, versus $15.2 million in 2021. There were no financing cash flows in 2022; 2021 included $55.6 million of financing proceeds.
- Liquidity: Cash and equivalents were $42.6 million at September 30, down from $55.1 million at year-end 2021. Working capital was $36.4 million; accumulated deficit was $458.3 million. Management said cash should fund operations and ongoing trials into 2024, while stating that additional financing will be needed to continue development and operations.
- Debt and liabilities: The filing reports no borrowings; total liabilities were $10.4 million, including $7.3 million current liabilities and $3.3 million deferred revenue. The filing does not provide a debt balance because no debt is reported.
- Margins: The company reported no meaningful product sales or gross-profit measure; revenue was minimal relative to operating expenses.
Material changes versus prior comparable periods
- Quarterly operating loss widened to $5.6 million from $4.0 million, largely reflecting higher R&D and the absence of the prior-year $530,000 gain from a change in warrant-liability fair value.
- Nine-month operating loss widened to $13.9 million from $12.7 million. Higher narazaciclib manufacturing, personnel, and stock-based compensation costs outweighed lower G&A and reduced clinical/consulting spending on the INSPIRE program.
- Cash declined by $12.5 million over the first nine months of 2022, compared with a $40.4 million increase in 2021, when substantial equity financing was raised.
Outlook, commentary, risks and unusual items
- Management expects continuing losses and says 2022 net cash expenditure should be slightly higher than in 2021. It anticipates higher clinical-trial costs as narazaciclib development advances and clinical and regulatory headcount increases.
- Management is pursuing dilutive and non-dilutive financing, including equity, alliances, and business-development arrangements. It warns that collaborations or licensing could require relinquishing valuable rights; funding may not be available on acceptable terms or at all. The company may delay, scale back, or eliminate activities if funding is insufficient.
- Narazaciclib Phase 1 studies were ongoing in the U.S. and China; the U.S. study’s fifth dose cohort was underway. The company planned to begin a Phase 1/2a narazaciclib-plus-letrozole trial in recurrent metastatic low-grade endometrioid endometrial cancer in Q1 2023.
- Rigosertib combination testing with a PD-1 inhibitor in KRAS-mutated NSCLC continued. Updated data cited one complete response, two partial responses, and one stable disease among 14 evaluable patients; additional data were anticipated in the first half of 2023. The filing also describes early monotherapy results in an ultra-rare cancer based on one patient, which management says warrant further study.
- After quarter-end, Nasdaq notified the company on November 7, 2022 that it did not meet the $1.00 minimum bid-price requirement. It had until May 8, 2023 to regain compliance, with a possible additional compliance period subject to conditions. Delisting could harm share liquidity and the company’s ability to raise capital.
- The company reported no material pending legal proceedings and said COVID-19 had not materially affected it through September 30, 2022, though future effects remained uncertain. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm the correct issuer: the supplied filing is Onconova Therapeutics, Inc., not Traws Pharma, Inc.
- Track cash burn, clinical and manufacturing spending, and whether management’s stated runway into 2024 remains achievable.
- Assess the timing, terms, and dilution or asset-rights implications of any required financing or partnership.
- Review clinical-trial progress and the evidentiary limits of the preliminary rigosertib data, including small patient counts.
- Check subsequent Nasdaq bid-price compliance and any potential listing or capital-raising consequences.